Core Viewpoint - Qualigen Therapeutics, Inc. has entered a non-binding Memorandum of Understanding (MOU) to acquire Marizyme, following a co-marketing agreement established in 2024, with the potential for rapid revenue growth beginning in 2025 [1][2][4]. Group 1: Acquisition Details - The MOU was dated March 28, 2025, and is a logical next step in the acquisition process, pending full due diligence and shareholder approval after filing an S4 [2]. - There is no assurance that the transaction will be completed or that definitive agreements will be executed [2]. Group 2: Product and Market Potential - Marizyme's DuraGraft is an FDA cleared platform technology in the Coronary Artery Bypass Graft (CABG) market, which generates over $10 billion in annual revenue [3]. - There are more than 500,000 CABG surgeries performed annually in the US, with saphenous vein graft (SVG) failure rates being a significant concern, as approximately 50% fail within 5 to 10 years [3]. - DuraGraft aims to prevent oxidative damage and slow the progression of vein graft failure, potentially increasing hospital savings by reducing repeat procedures and hospital stays [3]. Group 3: Management Statements - The CEO of Qualigen expressed excitement about the acquisition, highlighting the potential for rapid revenue growth starting in 2025 [4]. - The CEO of Marizyme noted that combining the two companies will leverage the FDA cleared DuraGraft medical device, with revenue expected by the end of fiscal 2025 [5].